Oncology Ventures is an Austin, Texas-based venture capital firm focused exclusively on companies improving cancer care. The firm closed Fund II at $62 million and was founded by Ben Freeberg, a cancer survivor who built the fund around the conviction that the people closest to the problem should be the ones funding the solutions. Oncology Ventures is anchored by a group of leading cancer care institutions — including Texas Oncology, Moffitt Cancer Center, City of Hope, Atlantic Health System, Cardinal Health, and Fred Hutch — whose clinical networks, patient data access, and procurement relationships are directly available to portfolio companies.
Oncology Ventures invests in companies across the cancer care continuum: diagnostics, treatment, care coordination, data infrastructure, and patient support. The firm is particularly interested in companies that can demonstrate clinical validity quickly, leveraging its institutional LP relationships for real-world evidence, pilot programs, and commercial pathways into cancer care networks. The focus spans software, AI, diagnostics, and tech-enabled services — all in the context of oncology specifically.
Oncology Ventures Fund II closed at $62 million, building on the firm's debut fund and expanding both its capital base and its LP network of cancer care institutions. The fund's anchor LPs (Texas Oncology, Moffitt Cancer Center, City of Hope, Atlantic Health System, Cardinal Health, and Fred Hutch) represent a combined patient reach of millions and institutional purchasing power that most healthcare funds cannot offer portfolio companies.
Fund II is structured to invest in early-to-growth-stage oncology companies, with check sizes appropriate for Series A and B rounds, though the firm also backs companies at earlier stages.
Leadership
Ben Freeberg is the Founder and Managing Partner of Oncology Ventures. His background as a cancer survivor shapes the firm's mission-driven approach and its emphasis on founder authenticity and patient-centered outcomes. The firm's advisory board includes Dr. Karen Knudsen, Nancy Brown, Brad Hively, Dr. Lee Newcomer, and Emily Melton, a combination of oncology clinical leadership, health policy, and technology investment expertise.
Investment Strategy
Oncology Ventures invests with access to a network of cancer care institutions that can serve as development partners, pilot sites, and commercial customers for portfolio companies. The firm looks for oncology-focused companies that are ready to engage with major cancer centers and health systems, and that can use those relationships to accelerate clinical validation and market adoption. The institutional LP base is the fund's primary differentiation: portfolio companies gain direct introductions to clinical leadership, procurement offices, and data teams at some of the country's most respected cancer centers.
Notable Investments
Oncology Ventures' Fund II portfolio includes companies across the cancer care technology stack:
Other
Oncology Ventures is one of the very few venture funds built specifically around institutional cancer care partners as LPs. For oncology-focused founders, this creates a pathway to clinical validation and commercial traction that is nearly impossible to replicate through traditional VC relationships. Founders building in cancer diagnostics, AI for oncology, care coordination, or any technology directly tied to the cancer care pathway should treat an Oncology Ventures introduction as one of the most high-leverage first meetings they can get.
United States
